DOCSLIB.ORG

Epilepsy in KCNH1-Related Syndromes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Epilepsy in KCNH1-Related Syndromes Journal Identification = EPD Article Identification = 0830 Date: June 8, 2016 Time: 10:40 am Original article Epileptic Disord 2016; 18 (2): 123-36 Epilepsy in KCNH1-related syndromes Mario Mastrangelo 1, Ingrid E. Scheffer 2, Nuria C. Bramswig 3, Lal. D.V. Nair 4, Candace T. Myers 5, Maria Lisa Dentici 6, Georg C. Korenke 7, Kelly Schoch 8, Philippe M. Campeau 9, Susan M. White 10,11, Vandana Shashi 8, Sujay Kansagra 12, Anthonie J. Van Essen 13, Vincenzo Leuzzi 1 1 Pediatric Neurology Division Department of Pediatrics, Child Neurology and Psychiatry, Sapienza-University of Rome, Rome, Italy 2 Florey Institute and University of Melbourne, Austin Health and Royal Children’s Hospital, Melbourne, Australia 3 Institut für Humangenetik, Universitätsklinikum Essen, Universität Duisburg-Essen, Germany 4 Department of Pediatrics, Saveetha Medical College, Chennai, India 5 Department of Pediatrics, University of Washington, Seattle, WA, USA 6 Bambino Gesù Children Hospital, Rome, Italy 7 Klinik für Neuropädiatrie, Klinikum Oldenburg, Germany 8 Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, USA 9 Department of Pediatrics, University of Montreal, Montreal, Canada 10 Victorian Clinical Genetics Services, Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne, Victoria, Australia 11 Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia 12 Division of Pediatric Neurology, Department of Pediatrics, Duke University Medical Center, Durham, USA 13 Department of Genetics, University of Groningen, University Medical Center Groningen, The Netherlands Received December 10, 2015; Accepted April 20, 2016 ABSTRACT – Aim. KCNH1 mutations have been identified in patients with Zimmermann-Laband syndrome and Temple-Baraitser syndrome, as well as patients with uncharacterized syndromes with intellectual disability and overlapping features. These syndromes include dysmorphic facial features, nail hypo/aplasia, thumb and skeletal anomalies, intellectual disability, and seizures. We report the epilepsy phenotype in patients with KCNH1 mutations. Methods. Demographic data, electroclinical features, response to antiepileptic drugs, and results of significant diagnostic investigations of nine patients carrying mutations in KCNH1 were obtained from referring centres. Results. Epilepsy was present in 7/9 patients. Both generalized and focal tonic-clonic seizures were observed. Complete seizure control was Correspondence: achieved with pharmacological treatment in 2/7 patients; polytherapy Vincenzo Leuzzi Pediatric Neurology Division, was required in 4/7 patients. Status epilepticus occurred in 4/7 patients. Department of Pediatrics, EEG showed a diffusely slow background in 7/7 patients with epilepsy, Child Neurology and Psychiatry, with variable epileptiform abnormalities. Cerebral folate deficiency and Sapienza-University of Rome, Italy an increase in urinary hypoxanthine and uridine were observed in one <[email protected]> doi:10.1684/epd.2016.0830 patient. Epileptic Disord, Vol. 18, No. 2, June 2016 123 Journal Identification = EPD Article Identification = 0830 Date: June 8, 2016 Time: 10:40 am M. Mastrangelo, et al. Conclusions. Epilepsy is a key phenotypic feature in most individuals with KCNH1-related syndromes, suggesting a direct role of KCNH1 in epilepto- genesis, although the underlying mechanism is not understood. Key words: Zimmermann-Laband syndrome, Temple-Baraitser syn- drome, genetic epilepsy, undefined intellectual disability, KCNH1-related encephalopathy KCNH1 (potassium channel, voltage-gated, subfamily Seizure semiology h, member 1; OMIM-603305) encodes a voltage-gated potassium channel (Kv10.1), with prominent expres- Epilepsy was present in 7/9 patients. Seizure onset sion in the brain, where it is involved in the regulation ranged from birth to eight months in 4/7 patients, of neurotransmitter release and synaptic transmission while in Patients 1, 7 and 9, onset was at 10 years, (Mortensen et al., 2015; Haitin et al., 2013). KCNH1 18 months, and 33 months, respectively. Febrile mutations have been recently demonstrated to have a seizures were observed in Patient 3 only. pathogenic role in two rare disorders: Zimmermann- Focal seizures (including clonic and versive seizures) Laband syndrome (ZLS- OMIM 135500) and Temple occurred in six patients, while generalized seizures Baraitser syndrome (TMBTS- OMIM 611816) (Kortüm (including myoclonic, tonic, clonic, and tonic-clonic) et al., 2015; Simons et al., 2015). These syndromes were reported in six patients (table 2). Photosensitive include dysmorphic facial features, nail hypo/aplasia, absence seizures were observed in Patients 3 and 9. thumb and skeletal anomalies, intellectual disability, Four of seven patients had convulsive status epilepti- and seizures (Bramswig et al., 2015; Kortüm et al., cus (table 2). 2015; Simons et al., 2015). Overlapping clinical pre- sentations have been reported in four cases from a Other clinical features cohort of individuals with uncharacterized intellectual disability (Bramswig et al., 2015). Here, we phenotype All patients had the previously reported pheno- the epilepsy features of patients with KCNH1-related typic hallmarks of KCNH1 disorders (Bramswig et syndromes. al., 2015; Kortüm et al., 2015; Simons et al., 2015). Nail hypo/aplasia was observed in all patients, except Patients and methods Patient 3. Neonatal problems, including neonatal asphyxia, res- The clinical history, including medical history and piratory distress, jaundice, neonatal seizures, and developmental course, seizure semiology, clinical feeding difficulties, were observed in 4/9 patients. examination, antiepileptic drugs treatment, EEG moni- Six of nine patients had hypotonia and 3/8 patients toring, and laboratory and neuroradiological data, was had movement disorders including tremor, choreo- collected for nine cases with KCNH1-related disorders. athetosis, oculo-motor apraxia, and ataxia. Of the eight published cases, five had ZLS and three uncharacterized intellectual disability (Rauch et al., 2012; Castori et al., 2013; Campeau et al., 2014; Bramswig EEG findings et al., 2015; Kortüm et al., 2015; Nair et al., 2015; Simons et al., 2015). A new case of a 12-month-old child with EEG studies showed diffuse background slowing in ZLS was also included. 8/9 patients (table 1). Multifocal epileptiform abnor- malities with prominent fronto-temporal foci were The genetic mutations were identified through whole- observed in 6/7 patients, while occipital foci were exome sequencing (Bramswig et al., 2015; Kortüm et found in 3/7 patients (table 2). A generalized spike-wave al., 2015). It was not possible to detect any of the after photic stimulation was detected in two patients patients’ mutations in their parents by Sanger sequenc- (table 2). As an example, EEG features of Patient 4 are ing (Bramswig et al., 2015; Kortüm et al., 2015). Parental shown in figure 1. mosaicism was similarly excluded (Bramswig et al., 2015; Kortüm et al., 2015). Parental written informed consent was obtained for all subjects. Other diagnostic investigations Results MRI showed non-specific abnormalities in 3/9 patients: ventricular asymmetry, cystic enlargement of the sub- Demographic, electroclinical, and genetic features of arachnoid spaces of the temporal lobes and dilatation nine patients (six female; aged 12 months to 28 years) of cavum vergae, increased extra-axial spaces, and cor- are summarized in table 1. pus callosal hypoplasia (table 1). 124 Epileptic Disord, Vol. 18, No. 2, June 2016 Journal Identification = EPD Article Identification = 0830 Date: June 8, 2016 Time: 10:40 am Epileptic Disord, Vol. 18, No. 2, June 2016 Table 1. Demographic, molecular genetics, and electro-clinical data of the reported series. PATIENTS PATIENT 1 PATIENT 2 PATIENT 3 PATIENT 4 PATIENT 5 PATIENT 6 PATIENT 7 PATIENT 8 PATIENT 9 Clinical Zimmermann- Zimmermann- Zimmermann- Zimmermann- Zimmermann- Zimmermann- Undefined Undefined Undefined diagnosis Laband Laband Laband Laband Laband Laband intellec- intellec- intellec- syndrome syndrome syndrome syndrome syndrome syndrome tual tual tual disability disability disability Reference Patient 1 Patient 2 Patient 4 Patient 5 Patient 6 Unpublished Patient 1 Patient 2 Patient 3 Kortüm et Kortüm et Kortüm et Kortüm et Kortüm et Bramswig Bramswig Bramswig al., 2015 al., 2015 al., 2015 al., 2015 al., 2015 et al., 2015 et al., 2015 et al., 2015 Age and 14 Years, F 28 years, M 14 years, F 10 years, M 8 years, F 12 months, M 15 years, F 5 years, F 5 years, F gender Place of Germany Australia Italy Italy India USA Germany Germany The birth Nether- lands KCNH1 c.1399A>G c.974C>A c.1405G>A c.1054C>G c.1399A>G c.1042G>A c.1070G>A; c.1070G>A; c.1070G>A; gene p.Ile467Val p.Ser325Tyr p.Gly469Arg p.Leu352Val p.Ile467Val p.Gly348Arg p.Arg330Gln p.Arg330Gln p.Arg357Gln mutation c.1066G>C p.Val356Leu Inheritance De novo De novo De novo De novo De novo De novo De novo De novo De novo Gestation Normal Normal Normal Normal Normal Normal Normal Normal Normal and gestation gestation gestation gestation gestation gestation gestation gestation gestation delivery Natural Forceps Caesarean Natural Natural Natural Caesarean Caesarean Caesarean delivery delivery section delivery dystocic delivery section section section because delivery of foetal (meconium Epilepsy in sufferance stained liquor, absent crying, KCNH1 requiring meco- -related syndromes nium suction and stimu- lation) 125 Journal Identification = EPD Article
Load more

Recommended publications
  • The Mineralocorticoid Receptor Leads to Increased Expression of EGFR
    www.nature.com/scientificreports OPEN The mineralocorticoid receptor leads to increased expression of EGFR and T‑type calcium channels that support HL‑1 cell hypertrophy Katharina Stroedecke1,2, Sandra Meinel1,2, Fritz Markwardt1, Udo Kloeckner1, Nicole Straetz1, Katja Quarch1, Barbara Schreier1, Michael Kopf1, Michael Gekle1 & Claudia Grossmann1* The EGF receptor (EGFR) has been extensively studied in tumor biology and recently a role in cardiovascular pathophysiology was suggested. The mineralocorticoid receptor (MR) is an important efector of the renin–angiotensin–aldosterone‑system and elicits pathophysiological efects in the cardiovascular system; however, the underlying molecular mechanisms are unclear. Our aim was to investigate the importance of EGFR for MR‑mediated cardiovascular pathophysiology because MR is known to induce EGFR expression. We identifed a SNP within the EGFR promoter that modulates MR‑induced EGFR expression. In RNA‑sequencing and qPCR experiments in heart tissue of EGFR KO and WT mice, changes in EGFR abundance led to diferential expression of cardiac ion channels, especially of the T‑type calcium channel CACNA1H. Accordingly, CACNA1H expression was increased in WT mice after in vivo MR activation by aldosterone but not in respective EGFR KO mice. Aldosterone‑ and EGF‑responsiveness of CACNA1H expression was confrmed in HL‑1 cells by Western blot and by measuring peak current density of T‑type calcium channels. Aldosterone‑induced CACNA1H protein expression could be abrogated by the EGFR inhibitor AG1478. Furthermore, inhibition of T‑type calcium channels with mibefradil or ML218 reduced diameter, volume and BNP levels in HL‑1 cells. In conclusion the MR regulates EGFR and CACNA1H expression, which has an efect on HL‑1 cell diameter, and the extent of this regulation seems to depend on the SNP‑216 (G/T) genotype.
    [Show full text]
  • Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short
    bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Transcriptomic analysis of native versus cultured human and mouse dorsal root ganglia focused on pharmacological targets Short title: Comparative transcriptomics of acutely dissected versus cultured DRGs Andi Wangzhou1, Lisa A. McIlvried2, Candler Paige1, Paulino Barragan-Iglesias1, Carolyn A. Guzman1, Gregory Dussor1, Pradipta R. Ray1,#, Robert W. Gereau IV2, # and Theodore J. Price1, # 1The University of Texas at Dallas, School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, 800 W Campbell Rd. Richardson, TX, 75080, USA 2Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine # corresponding authors [email protected], [email protected] and [email protected] Funding: NIH grants T32DA007261 (LM); NS065926 and NS102161 (TJP); NS106953 and NS042595 (RWG). The authors declare no conflicts of interest Author Contributions Conceived of the Project: PRR, RWG IV and TJP Performed Experiments: AW, LAM, CP, PB-I Supervised Experiments: GD, RWG IV, TJP Analyzed Data: AW, LAM, CP, CAG, PRR Supervised Bioinformatics Analysis: PRR Drew Figures: AW, PRR Wrote and Edited Manuscript: AW, LAM, CP, GD, PRR, RWG IV, TJP All authors approved the final version of the manuscript. 1 bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Ion Channels 3 1
    r r r Cell Signalling Biology Michael J. Berridge Module 3 Ion Channels 3 1 Module 3 Ion Channels Synopsis Ion channels have two main signalling functions: either they can generate second messengers or they can function as effectors by responding to such messengers. Their role in signal generation is mainly centred on the Ca2 + signalling pathway, which has a large number of Ca2+ entry channels and internal Ca2+ release channels, both of which contribute to the generation of Ca2 + signals. Ion channels are also important effectors in that they mediate the action of different intracellular signalling pathways. There are a large number of K+ channels and many of these function in different + aspects of cell signalling. The voltage-dependent K (KV) channels regulate membrane potential and + excitability. The inward rectifier K (Kir) channel family has a number of important groups of channels + + such as the G protein-gated inward rectifier K (GIRK) channels and the ATP-sensitive K (KATP) + + channels. The two-pore domain K (K2P) channels are responsible for the large background K current. Some of the actions of Ca2 + are carried out by Ca2+-sensitive K+ channels and Ca2+-sensitive Cl − channels. The latter are members of a large group of chloride channels and transporters with multiple functions. There is a large family of ATP-binding cassette (ABC) transporters some of which have a signalling role in that they extrude signalling components from the cell. One of the ABC transporters is the cystic − − fibrosis transmembrane conductance regulator (CFTR) that conducts anions (Cl and HCO3 )and contributes to the osmotic gradient for the parallel flow of water in various transporting epithelia.
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • Modulation of Voltage-Gated Potassium Channels by Phosphatidylinositol-4,5-Bisphosphate Marina Kasimova
    Modulation of voltage-gated potassium channels by phosphatidylinositol-4,5-bisphosphate Marina Kasimova To cite this version: Marina Kasimova. Modulation of voltage-gated potassium channels by phosphatidylinositol-4,5- bisphosphate. Other. Université de Lorraine, 2014. English. NNT : 2014LORR0204. tel-01751176 HAL Id: tel-01751176 https://hal.univ-lorraine.fr/tel-01751176 Submitted on 29 Mar 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. AVERTISSEMENT Ce document est le fruit d'un long travail approuvé par le jury de soutenance et mis à disposition de l'ensemble de la communauté universitaire élargie. Il est soumis à la propriété intellectuelle de l'auteur. Ceci implique une obligation de citation et de référencement lors de l’utilisation de ce document. D'autre part, toute contrefaçon, plagiat, reproduction illicite encourt une poursuite pénale. Contact : [email protected] LIENS Code de la Propriété Intellectuelle. articles L 122. 4 Code de la Propriété Intellectuelle. articles L 335.2- L 335.10 http://www.cfcopies.com/V2/leg/leg_droi.php
    [Show full text]
  • HCN2 Rescues Brain Defects by Enforcing Endogenous Voltage Pre-Patterns
    ARTICLE DOI: 10.1038/s41467-018-03334-5 OPEN HCN2 Rescues brain defects by enforcing endogenous voltage pre-patterns Vaibhav P. Pai 1, Alexis Pietak1, Valerie Willocq1, Bin Ye2, Nian-Qing Shi3 & Michael Levin1 Endogenous bioelectrical signaling coordinates cell behaviors toward correct anatomical outcomes. Lack of a model explaining spatialized dynamics of bioelectric states has hindered the understanding of the etiology of some birth defects and the development of predictive 1234567890():,; interventions. Nicotine, a known neuroteratogen, induces serious defects in brain patterning and learning. Our bio-realistic computational model explains nicotine’s effects via the dis- ruption of endogenous bioelectrical gradients and predicts that exogenous HCN2 ion chan- nels would restore the endogenous bioelectric prepatterns necessary for brain patterning. Voltage mapping in vivo confirms these predictions, and exogenous expression of the HCN2 ion channel rescues nicotine-exposed embryos, resulting in normal brain morphology and molecular marker expression, with near-normal learning capacity. By combining molecular embryology, electrophysiology, and computational modeling, we delineate a biophysical mechanism of developmental brain damage and its functional rescue. 1 Allen Discovery Center at Tufts University, Medford, MA 02155, USA. 2 Veridian Biotechnology Limited, Biotech Center 2, Hong Kong, China. 3 Department of Developmental, Molecular, and Chemical Biology, Tufts University, Boston, MA 02111, USA. Correspondence and requests for materials
    [Show full text]
  • Gene List of the Targeted NGS MCD and CCA Gene Panel AKT3,ALX1
    Gene List of the targeted NGS MCD and CCA gene panel AKT3,ALX1,ALX3,ALX4,AMPD2,ARFGEF2,ARID1B,ARX,ASPM,ATR,ATRX,B3GALTL,BRPF1,c12orf57,C6orf70,CASK,CCND2,CDK5RAP2,CDON,C ENPJ,CEP170,CHMP1A,COL4A1,CREBBP,CYP11A1,DCHS1,DCLK1,DCX,DHCR24,DHCR7,DIS3L2,DISC1,DISP1,DLL1,DMRTA2,DYNC1H1,DYRK1 A,EARS2,EFNB1,EMX1,EOMES,EP300,ERBB4,ERMARD,EXOSC3,FAM36A,FGF8,FGFR1,FGFR2,FLNA,FOXC1,FOXG1,FOXH1,FZD10,GLI2,GLI3,GP R56,GPSM2,HCCS,HESX1,HNRNPU,IGBP1,IGFBP1,ISPD,ITPA,KAL1,KAT6B,KATNB1,KIAA1279,KIF14,KIF1A,KIF1B,KIF21A,KIF2A,KIF5C,KIF7,L1 CAM,LAMB1,LAMC3,LRP2,MCPH1,MED12,MID1,NDE1,NFIB,NPC1,NR2F1,NSD1,NTRK1,NTRK3,OCEL1,OPA1,OTX2,PAFAH1B1,PAX6,PEX1,PHF1 0,PIK3R2,POLR3A,POLR3B,POMT1,POMT2,PTCH1,PTPRS,PYCR1,RAB3GAP1,RARS2,RELN,RFX3,ROBO1,ROBO3,RPS6KA3,RTTN,SATB2,SEPSEC S,SHH,SIX3,SLC12A6,SOX2,SPOCK1,SRPX2,TBCD,TBCE,TCF4,TDGF1,TEAD1,THBS2,TMEM5,TSC1,TSC2,TSEN15,TSEN2,TSEN34,TSEN54,TUBA1 A,TUBA8,TUBB,TUBB2A,TUBB2B,TUBB3,TUBB4A,TUBG1,VAX1,VRK1,WDR47,WDR62,ZBTB18,ZEB2,ZIC2. Gene List of the targeted NGS epilepsy gene panel AARS, ADGRV1, ADRA2B, ADSL, ALDH4A1, ALDH7A1, ALG13, ALPL, ARHGEF15, ARHGEF9, ARX, ASAH1, ATP1A2, ATP1A3, BRD2, CACNA1A, CACNA1H, CACNA2D2, CACNB4, CBL, CDKL5, CERS1, CHD2, CHRNA2, CHRNA4, CHRNB2, CLCN2, CLCN4, CLN8, CLTC, CNKSR2, CNTNAP2, CPA6, CPLX1, CSNK1G1, CSNK2B, CTNND2, DEPDC5, DHDDS, DNM1, DOCK7, DYNC1H1, EEF1A2, EFHC1, EIF2S3, EMC1, EPM2A, FASN, FLNA, FOXG1, GABBR2, GABRA1, GABRA2, GABRA3, GABRB2, GABRB3, GABRD, GABRG2, GAL, GNAO1, GOSR2, GRIA1, GRIN1, GRIN2A, GRIN2B, HCN1, HCN4, HDAC4, HNRNPU, IDH3A, IQSEC2, JRK, KCNA1, KCNA2, KCNB1,
    [Show full text]
  • KCNH1 (C-11): Sc-398585
    SANTA CRUZ BIOTECHNOLOGY, INC. KCNH1 (C-11): sc-398585 BACKGROUND APPLICATIONS Voltage-gated potassium channels play an essential role in controlling cellu- KCNH1 (C-11) is recommended for detection of KCNH1 of mouse, rat and lar excitability in the nervous system. They regulate a variety of properties human origin by Western Blotting (starting dilution 1:100, dilution range including membrane potential as well as the frequency and structure of 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein action potentials. KCNH1 (potassium voltage-gated channel, subfamily H (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution (eag-related), member 1), also known as ether-a-go-go potassium channel 1, range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution voltage-gated potassium channel subunit Kv10.1, EAG, EAG1 or h-eag, is a range 1:30-1:3000). 989 amino acid multi-pass membrane protein belonging to the potassium Suitable for use as control antibody for KCNH1 siRNA (h): sc-78963, KCNH1 channel family and H (Eag) subfamily. KCNH1 is highly expressed in myoblasts siRNA (m): sc-146362, KCNH1 shRNA Plasmid (h): sc-78963-SH, KCNH1 and brain, forms two alternatively spliced isoforms and exists as a pore- shRNA Plasmid (m): sc-146362-SH, KCNH1 shRNA (h) Lentiviral Particles: forming (α) subunit of a voltage-gated non-inactivating delayed rectifier sc-78963-V and KCNH1 shRNA (m) Lentiviral Particles: sc-146362-V. potassium channel. Encoded by a gene located on human chromosome 1, KCNH1 forms a heteromultimer with KCNH5 and also interacts with ALG10.
    [Show full text]
  • EGL Test Description
    2460 Mountain Industrial Boulevard | Tucker, Georgia 30084 Phone: 470-378-2200 or 855-831-7447 | Fax: 470-378-2250 eglgenetics.com Epilepsy and Seizure Disorders Panel: Sequencing and CNV Analysis Test Code: MEPI1 Turnaround time: 6 weeks CPT Codes: 81404 x1, 81406 x1, 81405 x1, 81175 x1, 81302 x1, 81403 x1, 81407 x1, 81409 x1, 81479 x1 Condition Description Epilepsy is defined as a disorder in which an individual has recurrent, unprovoked seizures. It has a prevalence of about 5-10 per 1000 people. While the causes of epilepsy are diverse, a significant proportion are considered to be genetic in origin. Epilepsy can occur as part of a clinical spectrum that is associated with a particular genetic syndrome, such as Mowat Wilson syndrome, Dravet syndrome, and “chromosomal” epilepsies. Common “chromosomal” epilepsies include 1p36 deletion syndrome, Wolf-Hirschhorn syndrome, Angelman syndrome, Miller-Dieker syndrome, 15q inversion- duplication, Down syndrome and ring chromosome 14 and 20. In addition, epilepsy can occur as an isolated finding, 40% of which are believed to be due to genetic causes. Approximately 2% of the genetic causes of isolated epilepsy are due to monogenetic causes while the rest are thought to be due to multifactorial genetic and environmental causes. Of the monogenetic genes identified, the majority code for ion channel subunits and neurotransmitter receptors. The Epilepsy and Seizure Disorders Panel is comprised of a next generation sequencing (NGS) for syndromic and non-syndromic causes of seizures. It is recommended that individuals with seizures have a chromosomal microarray as a first tier test. Please click here for information on our EmArray Cyto and CytoScan SNP Array.
    [Show full text]
  • Perkinelmer Genomics to Request the Saliva Swab Collection Kit for Patients That Cannot Provide a Blood Sample As Whole Blood Is the Preferred Sample
    Autism and Intellectual Disability TRIO Panel Test Code TR002 Test Summary This test analyzes 2429 genes that have been associated with Autism and Intellectual Disability and/or disorders associated with Autism and Intellectual Disability with the analysis being performed as a TRIO Turn-Around-Time (TAT)* 3 - 5 weeks Acceptable Sample Types Whole Blood (EDTA) (Preferred sample type) DNA, Isolated Dried Blood Spots Saliva Acceptable Billing Types Self (patient) Payment Institutional Billing Commercial Insurance Indications for Testing Comprehensive test for patients with intellectual disability or global developmental delays (Moeschler et al 2014 PMID: 25157020). Comprehensive test for individuals with multiple congenital anomalies (Miller et al. 2010 PMID 20466091). Patients with autism/autism spectrum disorders (ASDs). Suspected autosomal recessive condition due to close familial relations Previously negative karyotyping and/or chromosomal microarray results. Test Description This panel analyzes 2429 genes that have been associated with Autism and ID and/or disorders associated with Autism and ID. Both sequencing and deletion/duplication (CNV) analysis will be performed on the coding regions of all genes included (unless otherwise marked). All analysis is performed utilizing Next Generation Sequencing (NGS) technology. CNV analysis is designed to detect the majority of deletions and duplications of three exons or greater in size. Smaller CNV events may also be detected and reported, but additional follow-up testing is recommended if a smaller CNV is suspected. All variants are classified according to ACMG guidelines. Condition Description Autism Spectrum Disorder (ASD) refers to a group of developmental disabilities that are typically associated with challenges of varying severity in the areas of social interaction, communication, and repetitive/restricted behaviors.
    [Show full text]
  • Potassium Channels and Their Potential Roles in Substance Use Disorders
    International Journal of Molecular Sciences Review Potassium Channels and Their Potential Roles in Substance Use Disorders Michael T. McCoy † , Subramaniam Jayanthi † and Jean Lud Cadet * Molecular Neuropsychiatry Research Branch, NIDA Intramural Research Program, Baltimore, MD 21224, USA; [email protected] (M.T.M.); [email protected] (S.J.) * Correspondence: [email protected]; Tel.: +1-443-740-2656 † Equal contributions (joint first authors). Abstract: Substance use disorders (SUDs) are ubiquitous throughout the world. However, much re- mains to be done to develop pharmacotherapies that are very efficacious because the focus has been mostly on using dopaminergic agents or opioid agonists. Herein we discuss the potential of using potassium channel activators in SUD treatment because evidence has accumulated to support a role of these channels in the effects of rewarding drugs. Potassium channels regulate neuronal action potential via effects on threshold, burst firing, and firing frequency. They are located in brain regions identified as important for the behavioral responses to rewarding drugs. In addition, their ex- pression profiles are influenced by administration of rewarding substances. Genetic studies have also implicated variants in genes that encode potassium channels. Importantly, administration of potassium agonists have been shown to reduce alcohol intake and to augment the behavioral effects of opioid drugs. Potassium channel expression is also increased in animals with reduced intake of methamphetamine. Together, these results support the idea of further investing in studies that focus on elucidating the role of potassium channels as targets for therapeutic interventions against SUDs. Keywords: alcohol; cocaine; methamphetamine; opioids; pharmacotherapy Citation: McCoy, M.T.; Jayanthi, S.; Cadet, J.L.
    [Show full text]
  • Prefrontal Co-Expression of Schizophrenia Risk Genes Is Associated with Treatment Response
    bioRxiv preprint doi: https://doi.org/10.1101/323428; this version posted May 16, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Title: Prefrontal co-expression of schizophrenia risk genes is associated with treatment response 2 in patients 3 4 One Sentence Summary: Schizophrenia risk genes co-expressed in the dorsolateral prefrontal cortex 5 are associated with clinical outcome in patients with schizophrenia. 6 7 Authors: Giulio Pergola1,†, Pasquale Di Carlo1,2,†, Andrew E. Jaffe2,3,4,5, Marco Papalino1, Qiang 8 Chen2, Thomas M. Hyde2,7,8, Joel E. Kleinman2,7, Joo Heon Shin2, Antonio Rampino1,10, Giuseppe 9 Blasi1,10, Daniel R. Weinberger2,6,8,9, Alessandro Bertolino1,10,* 10 11 Affiliations: 12 1Group of Psychiatric Neuroscience, Department of Basic Medical Sciences, Neuroscience and Sense 13 Organs, University of Bari Aldo Moro, Bari, Italy 14 2Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland, 15 USA 16 3Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, 17 Maryland, USA 18 4Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 19 USA 20 5Center for Computational Biology, Johns Hopkins University, Baltimore, Maryland, USA 21 6Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland, USA 22 7Department of Neurology, Johns Hopkins School of Medicine, Baltimore, 1 bioRxiv preprint doi: https://doi.org/10.1101/323428; this version posted May 16, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]